Results 91 to 100 of about 27,363 (202)

A Critical Analysis of the Impact of Etoposide as a Topoisomerase II Inhibitor in Cervical Cancer Treatment: A Review

Cancer Medicine, Volume 15, Issue 3, March 2026.
Etoposide mediated topoisomerase II inhibition in Cervical Cancer. ABSTRACT Background Etoposide is a semisynthetic derivative of podophyllotoxin and an FDA‐approved topoisomerase II inhibitor that induces DNA strand breaks leading to cancer cell death.
Nikitha Kotian, Yashaswini Reddy, Padmini Pai, Babitha Kampa Sundara   +3 more
wiley   +1 more source

Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials [PDF]

, 2009
Background Evidence that chemotherapy improves survival and quality of life in patients with stage IIIB & IV non small cell lung cancer (NSCLC) is based on large randomized controlled trials.
Janette Vardy, Ryan Dadasovich, Philip Beale, Michael Boyer, Stephen J Clarke   +4 more
core   +2 more sources

Nivolumab in combination with AVD as frontline treatment for patients with classic Hodgkin lymphoma: A real‐world analysis from 20 US centers

HemaSphere, Volume 10, Issue 4, April 2026.
Allison M. Bock, Peirong Hao, Yizhe Xu, Efrat Luttwak, Swetha Kambhampati Thiruvengadam, Kanithra Sekaran, Dahlia Sano, John Vaughn, John Sharp, Ajay Major, Vrutti Patel, Gordon Smilnak, Nicole Araujo, Ritwick Mynam, Daniel Reef, Marisa Palmeri, Drew Gerber, Anuja Abhyankar, Grace Baek, Ayo Falade, Madiha Iqbal, Boyu Hu, Praveen Ramakrishnan Geethakumari, Urshila Durani, Mengyang Di, Alex Niu, Hua‐Jay J. Cherng, Joanna M. Rhodes, Natalie Grover, Priyanka Pophali, Tatyana Feldman, Krithika Shanmugasundaram, Jakub Svoboda, Timothy Voorhees, Catherine Diefenbach, Yasmin Karimi, Reem Karmali, Alex F. Herrera, Pallawi Torka, Narendranath Epperla   +39 more
wiley   +1 more source

Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patients. [PDF]

, 2015
BackgroundKetoconazole is a well-known CYP17-targeted systemic treatment for castration-resistant prostate cancer (CRPC). However, most of the published data has been in the pre-chemotherapy setting; its efficacy in the post-chemotherapy setting has not ...
Beckett, LA, Lara, PN, Lo, EN, Pan, CX, Robles, D, Sands, JM, Suga, JM   +6 more
core  

Male breast cancer [PDF]

, 2017
Male breast cancer (MBC) is a rare disease representing less than 1% of all breast cancers (BC) and less than 1% of cancers in men. Age at presentation is mostly in the late 60s.
A Bjørnerem, A Holleb, A Jemal, AC Antoniou, AM Shaaban, B D'Avanzo, Breast Cancer Linkage Consortium, C Gómez-Raposo, C Martinez-Bouzas, C Rudlowski, D Albo, D Ly, D Palli, DA Rigoni-Stern, DG Evans, DS Popovic, E Kreiter, EF Lewison, G Masci, G Ribeiro, GR Brown, I Ganly, I Sosnovskikh, I Zanna, IS Fentiman, IS Fentinam, J Boyd, J White, JD Fackenthal, JH Breasted, JL Gnerlich, JR Weiss, K Coard, K Syrjakoski, KA Johansen Taber, KD Crew, L France, L Ottini, L Ottini, LA Brinton, LA Brinton, LA Brinton, LA Brinton, LA Brinton, LA Korde, M Falchetti, M Golshan, MA Adank, MB Cook, ME Meijer-van Gelder, MM Munoz de Toro, MT Vietri, N Orr, N Rahman, O Gentilini, P Karamanakos, RM Ferzoco, S Paik, S Peng, S Shak, S Thorlacious, SH Giordano, SH Giordano, SH Giordano, T Grenader, V Silvestri, V Silvestri, V Speirs, WF Anderson, WF Anderson, Y Ge, ZI Mitri   +71 more
core   +1 more source

Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a Literature-based Meta-analysis. [PDF]

, 2009
Although platinum-based combinations are considered the best option of care for patients with advanced nonsmall cell lung cancer (NSCLC), single-agent therapy is the preferred treatment for older patients.
Adamo, V, CARRECA, Ignazio, FULFARO, Fabio, GEBBIA, Nicolo', Rizzo, S, RUSSO, Antonio, Santini, D, Vincenzi, B   +7 more
core   +1 more source

A Meta-Analysis of Platinum Plus Gemcitabine or Vinorelbine for Advanced Non-small Cell Lung Cancer

Chinese Journal of Lung Cancer, 2009
Background and objective Platinum plus the third-generation agent doublet chemotherapy is the standard regimens and first line chemotherapy for advanced non-small cell lung cancer (NSCLC).
Guanghui GAO, Xinli ZHOU, Ruofan HUANG, Zhaohui CHU, Qiong ZHAN, Xiaohua LIANG   +5 more
doaj  

David Slays Goliath: Exceptional Efficacy of Oral Vinorelbine in Conquering Metastatic Finger Angiosarcoma

Journal of Cancer Research and Practice
Angiosarcoma (AS) is a rare and aggressive disease originating from blood or lymphatic vessel endothelium, representing
Te-Lin Hsu, San-Chi Chen
doaj   +1 more source

Tumor Microenvironmental Responsive Liposomes Simultaneously Encapsulating Biological and Chemotherapeutic Drugs for Enhancing Antitumor Efficacy of NSCLC [Corrigendum]

International Journal of Nanomedicine, 2021
Kong L, Zhang S, Chu J, et al. Int J Nanomedicine. 2020;15:6451–6468. The authors have advised due to an error at the time of figure assembly, Figure 6A on page 6463 is incorrect. The correct Figure 6 is shown in Download Article.
Kong L, Zhang S, Chu J, Liu X, Zhang L, He S, Yang S, Ju R, Li X   +8 more
doaj  

Biological subtyping of early breast cancer : a study comparing RT-qPCR with immunohistochemistry [PDF]

, 2016
The biological subtype of breast cancer influences the selection of systemic therapy. Distinction between luminal A and B cancers depends on consistent assessment of Ki-67, but substantial intra-observer and inter-observer variability exists when ...
Auvinen, Paivi, Eidt, Sebastian, Heikkila, Paivi, Isola, Jorma, Joensuu, Heikki, Jyrkkio, Sirkku, Kellokumpu-Lehtinen, Pirkko-Liisa, Laible, Mark, Lakis, Sotiris, Sahin, Ugur, Schlombs, Kornelia, Sihto, Harri, Turpeenniemi-Hujanen, Taina, Weber, Stefan, Wirtz, Ralph M.   +14 more
core   +2 more sources